Vimarsana
Biggest News Aggregation in the World

Primary Human Cells News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Human Cells. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Human Cells Today - Breaking & Trending Today

MatTek Corporation : Quotes, Address, Contact - Vimarsana News

MatTek Corporation : Quotes, Address, Contact

For more than 25 years, MatTek has been the world leader in reliable in vitro human tissue model innovation.

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates - Vimarsana News

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data... | March 3, 2023

Frontiers | The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer - Vimarsana News

Frontiers | The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a devastating necrotizing skin disease. Key to its pathogenesis is mycolactone, the exotoxin virulence factor that is both immunosuppressive and cytotoxic. The discovery that the essential Sec61 translocon is the major cellular target of mycolactone explains much of the disease pathology, including the immune blockade. Sec61 inhibition leads to a loss in production of nearly all cytokines from monocytes, macrophages, dendritic cells and T cells, as well as antigen presentation pathway proteins and costimulatory molecules. However, there h...